tipepidine hibenzate
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2013 (NCT01835847)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCCC(=C(c2cccs2)c2cccs2)C1- Mol. weight
- 275.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1899506 ↗
Also known as
- asverin
- at-327
- at-327
- crj662
- crj662
- tipedine
- tipepidine
- tipepidine
- tipepidine
- tipepidine
- tipepidine
- tipepidine citrate (1:1)
- tipepidine hibenzate
- tipepidine hibenzate
- tipepidine hibenzate
- tipepidine hibenzate
- tipepidine hibenzate
- tipepidine hibenzate
- tipepidine ibenzato
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02305134 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Chiba University |
| NCT01835093 | Phase 2 | Apr 1, 2013 | Chiba University |
| NCT01835847 | Phase 2 | Apr 1, 2013 | Chiba University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chiba University | Academic/Hospital | 3 | 3 | 1 | 2013 |
1 organizations
Page 1 / 1